Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resatorvid in severe sepsis
NCT00143611Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of resatorvid in sepsis (3 arms), sponsored by Takeda. Primary endpoint: 28-day All-cause Mortality. Started Sep 2005; status: completed.
02
Drugs
resatorvid
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00143611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143611.